GNCA Genocea Biosciences Inc

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in preclinical stage, designed to direct a patient's immune system to attack tumor. The company is also seeking partners to develop cancer vaccines targeting tumor-associated antigens and a vaccine targeting cancers caused by Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

$2.35
As of 05/07/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/05/2014
Outstanding shares:  54,434,839
Average volume:  300,569
Market cap:   $133,365,356
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    372427401
ISIN:        US3724274010
Sedol:      BJ028Z9
Valuation   (See tab for details)
PE ratio:   -7.95
PB ratio:   1.98
PS ratio:   98.13
Return on equity:   -2,431.56%
Net income %:   -3,152.61%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy